• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
        • NTM Lung Disease
        • Bronchiectasis
        • Pulmonary Arterial Hypertension
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Programs
      • Pipeline
      • Clinical Trials
      • Our Research Team
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Aug 4, 2010
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2010
  • Jul 28, 2010
    Insmed to Host Second Quarter 2010 Conference Call
  • Jun 21, 2010
    Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
  • May 6, 2010
    Insmed Announces First Quarter 2010 Financial Results
  • Apr 22, 2010
    Insmed to Host First Quarter 2010 Conference Call
  • Mar 22, 2010
    Pharmaceutical Industry Veteran Nicholas LaBella Jr., MS, RPh, Joins Insmed as Chief Scientific Officer
  • Mar 15, 2010
    Insmed Announces Fourth Quarter and Full-Year 2009 Financial Results
  • Mar 4, 2010
    Insmed Regains NASDAQ Compliance
  • Mar 3, 2010
    Insmed to Host Fourth Quarter and Full-Year 2009 Conference Call
  • Nov 6, 2009
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
  • Oct 22, 2009
    Insmed To Host Third Quarter 2009 Conference Call
  • Sep 16, 2009
    Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
  • Aug 13, 2009
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
  • Jul 31, 2009
    Insmed to Host Second Quarter 2009 Conference Call
  • Jul 27, 2009
    Insmed Provides Update on Supply of IPLEX(TM)
  • Jun 30, 2009
    Insmed Announces Addition to the Russell 3000(R) Index
  • Jun 25, 2009
    Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
  • Jun 15, 2009
    Insmed CEO Resigns Due to Health Concerns
  • May 13, 2009
    Insmed Announces First Quarter 2009 Financial Results
  • May 5, 2009
    Insmed Regains NASDAQ Compliance
  • Apr 23, 2009
    Insmed to Host First Quarter 2009 Conference Call
  • Apr 22, 2009
    Insmed to Host First Quarter 2009 Conference Call
  • Mar 31, 2009
    Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
  • Mar 30, 2009
    Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
  • Mar 25, 2009
    Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
  • Mar 11, 2009
    Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
  • Mar 10, 2009
    Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
  • Feb 26, 2009
    Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
  • Feb 12, 2009
    Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
  • Jan 21, 2009
    Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
  • Dec 26, 2008
    Insmed to Appeal Delisting Notification From Nasdaq
  • Dec 23, 2008
    Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule
  • Nov 25, 2008
    Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
  • Nov 18, 2008
    Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation
  • Nov 10, 2008
    Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
  • Nov 5, 2008
    Insmed to Present at Upcoming Healthcare Conferences
  • Oct 30, 2008
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
    • Photos 4
  • Oct 22, 2008
    NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009
  • Oct 21, 2008
    Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
  • Oct 20, 2008
    Insmed to Host Third Quarter 2008 Conference Call
  • Oct 14, 2008
    Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
  • Oct 14, 2008
    Insmed to Seek Shareholder Approval for Reverse Split
  • Sep 23, 2008
    Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
  • Sep 15, 2008
    Insmed to Present at Biosimilars 2008 Conference
  • Sep 4, 2008
    Insmed to Present at BioPharm Asia 2008 Conference
  • Sep 3, 2008
    NASDAQ Hearing Panel Grants Insmed Request for Continued Listing on the NASDAQ Stock Market
  • Aug 8, 2008
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
  • Jul 28, 2008
    Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process Development
  • Jul 25, 2008
    Insmed to Host Second Quarter 2008 Conference Call
  • Jul 25, 2008
    Insmed CEO to Present at Drug Discovery & Development Conference
Show 5102550100 per page
  • «
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2022 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2022 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy